Overview

A Randomized, Open-label Clinical Trial, Focus on the Safety and Efficacy of Anlotinib Hydrochloride in Combination With RAI in Patients With Local Advanced and Tyriod Cancer

Status:
Not yet recruiting

Trial end date:
2024-07-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of anlotinib in combination with I-131 in locally advanced/metastatic differentiated thyroid cancer. Anlotinib may stop the growth of tumor cells and improve iodine uptake.

Phase:

Phase 2

Details

Lead Sponsor:

Peking Union Medical College Hospital

Collaborator:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.